# CONTENTS

<table>
<thead>
<tr>
<th>ABBREVIATIONS</th>
<th>I</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIST OF TABLES</td>
<td>II</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>III</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>IV</td>
</tr>
</tbody>
</table>

## CHAPTER 1

### INTRODUCTION

1.1 Human Papilloma Virus
1.2 HPV infection and its detection
1.3 Cervical cancer
1.4 HPV Vaccines
1.5 Justification of the work
Objectives

## CHAPTER 2

### REVIEW OF LITERATURE

2.1 Human Papillomavirus Classification
2.2 Association with Cervical cancer
2.3 Genomic Organization
2.4 The viral Proteins E 7
2.5 HPV 16 E 7 life cycle
2.6 Principles of HPV Vaccine for Cervical Cancer
2.7 Gene Expression Profile of HPV 16 E 7 in Squamous Cervical Carcinoma
2.8 Effect of HPV E 7 on cellular metabolism
2.9 Human TMEM 50 A

Run-length encoded text:

<table>
<thead>
<tr>
<th>ABBREVIATIONS</th>
<th>I</th>
</tr>
</thead>
<tbody>
<tr>
<td>LIST OF TABLES</td>
<td>II</td>
</tr>
<tr>
<td>LIST OF FIGURES</td>
<td>III</td>
</tr>
<tr>
<td>ABSTRACT</td>
<td>IV</td>
</tr>
</tbody>
</table>

## CHAPTER 1

### INTRODUCTION

1.1 Human Papilloma Virus
1.2 HPV infection and its detection
1.3 Cervical cancer
1.4 HPV Vaccines
1.5 Justification of the work
Objectives

## CHAPTER 2

### REVIEW OF LITERATURE

2.1 Human Papillomavirus Classification
2.2 Association with Cervical cancer
2.3 Genomic Organization
2.4 The viral Proteins E 7
2.5 HPV 16 E 7 life cycle
2.6 Principles of HPV Vaccine for Cervical Cancer
2.7 Gene Expression Profile of HPV 16 E 7 in Squamous Cervical Carcinoma
2.8 Effect of HPV E 7 on cellular metabolism
2.9 Human TMEM 50 A
## 2.10 Bioinformatics Approaches

### 2.11 In-Silico Proteome Analysis of HPV 16 E 7 and Human TMEM 50 A

### 2.12 Immunoinformatics and Vaccine Designing

### 2.13 In-Silico Epitope prediction

## CHAPTER 3 MATERIALS AND METHODS

### 3.1 HPV 16 E 7 Protein sequence retrieval and analysis

#### 3.1.1 Primary structure Analysis for HPV 16 E7 protein

#### 3.1.2 Secondary structure Analysis for HPV 16 E7 protein

#### 3.1.3 Multiple sequence alignment

#### 3.1.4 Phylogenetic Analysis of HPV 16 E7

### 3.2 Prediction of families and domains in HPV 16 E 7 and Human TMEM 50 A

### 3.3 Sequence Analysis of TMEM 50 A (Human Transmembrane protein)

#### 3.3.1 Characterization of target sequence

### 3.4 Prediction of disordered regions in HPV16 E7

### 3.5 Homology modelling for HPV type 16 E 7 Protein

### 3.6 Molecular Dynamics Simulation study of the predicted model of HPV 16 E 7

### 3.7 Virtual screening for validated model structure of HPV 16 E 7 Protein

### 3.8 Homology modelling for Human TMEM 50 A using I-TRASSER Server
### 3.9 Model refinement and Evaluation

3.10 Active site prediction of TMEM 50 A Protein

3.11 Computational epitope prediction for HPV 16 E7 Protein

3.12 Docking of Human TMEM 50 A and modeled T-cell epitopes of HPV 16 E7 antigens

3.13 Prediction of Protein-Protein interaction of docked molecules

---

### CHAPTER 4 RESULTS AND DISCUSSION

4.1 HPV16 E7 protein sequence retrieval and analysis

4.2 Predicted disordered regions and globularity of HPV 16 E7

4.3 T-COFFEE Analysis

4.4 Phylogenetic tree analysis of HPV 16 E7

4.5 Predicted families, Domains and Motifs in Human Papilloma Virus 16 E7 and Human TMEM 50 A

4.6 Characterisation of TMEM 50A (Human protein)

4.7 Model building, refinement and evaluation for modeled structure of the HPV 16 E7 Protein

4.8 Z-score Analysis

4.9 The Molecular Dynamics Simulation of the HPV16 E7

4.10 Virtual screening for validated model

---

31-69
<table>
<thead>
<tr>
<th>Structure of HPV 16 E7 Protein</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.11 Model refinement and evaluation of Human TMEM 50 A Protein</td>
</tr>
<tr>
<td>4.12 Active site prediction of Human TMEM 50 A</td>
</tr>
<tr>
<td>4.13 B-cell epitope binding peptide prediction</td>
</tr>
<tr>
<td>4.14 MHC Class-1 binding epitope Prediction</td>
</tr>
<tr>
<td>4.15 MHC Class-2 binding epitope Prediction</td>
</tr>
<tr>
<td>4.16 Docking of MHC Class-1 modeled epitopes and Human TMEM 50A</td>
</tr>
<tr>
<td>4.17 Docking of MHC Class-2 modeled epitopes and Human TMEM 50A</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>SUMMARY AND CONCLUSION</th>
</tr>
</thead>
<tbody>
<tr>
<td>70-74</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>REFERENCES</th>
</tr>
</thead>
<tbody>
<tr>
<td>75-87</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>PAPERS PUBLISHED</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>SUPPLEMENTARY MATERIAL</th>
</tr>
</thead>
</table>